APLNR and breast cancer: We also explored whether Apela, the recently described second ligand for Apelin receptor (Pauli et al, 2014), might also be overexpressed in NeuT‐driven mammary tumors or KRas‐driven lung tumors, but we failed to detect its expression, even using sensitive and multi‐cycle qPCR analysis.